BioLineRx upgraded to Buy from Hold at JonesResearch

JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot phase data from the investigator-initiated Phase II combination trial of motixafortide plus PD-1 inhibitor cemiplimab plus chemo in first line pancreatic cancer where seven of 11 patients responded to therapy and 10 of 11 achieved disease control, the analyst tells investors in a research note. With these results, the firm believes BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial assuming favorable Phase II results. It sees potential for more favorable stock momentum first line pancreatic cancer “in play.”